For Merck, Outcomes Trials Offer Fast Track To Payers
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
More so than any other big pharma, Merck is dependent on large outcomes trials. The cost of failure is high, but success would allow entry into massive, highly generic primary care markets with products backed by clinical outcomes data that meet payers’ need for real-world evidence of a drug’s value in terms of health economics as well as clinical efficacy.